High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 4, 2012, Pages 655-661

  Micalessi, Isabel M ^a   Boulet, Galle A V ^a   Bogers, Johannes J ^a,b   Benoy, Ina H ^b   Depuydt, Christophe E ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b RIATOL ^*  (Belgium)

Author keywords

cervical screening; genotype; human papillomavirus; real time PCR; viral load

Indexed keywords

BETA GLOBIN;

ARTICLE; CONTROLLED STUDY; CYTOLOGY; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 67; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VALIDATION STUDY; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

DNA, VIRAL; FEMALE; GENOTYPING TECHNIQUES; HUMANS; PAPILLOMAVIRIDAE; REAL-TIME POLYMERASE CHAIN REACTION; VIRAL LOAD;

HUMAN PAPILLOMAVIRUS;

EID: 84860437629     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm.2011.835     Document Type: Article

References (37)

1. Arbyn M, CastellsaguéX, de SanjoséS, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86.
2. Baldwin P, Laskey R, Coleman N. Translational approaches to improving cervical screening. Nat Rev Cancer 2003;3:217-26. (Pubitemid 37328873)
3. Wright TC Cervical cancer screening in the 21 st century: Is it time to retire the PAP smear ? Clin Obst Gynecol 2007;50:313-23
4. Bosch FX, Lorincz A, Mu ñ oz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65. (Pubitemid 34293391)
5. Boulet GA, Horvath CA, Berghmans S, Bogers J. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev 2008;17:810-7. (Pubitemid 351536410)
6. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Effi cacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-57.
7. Arbyn M, Ronco G, Meijer CJ, Naucler P. Trials comparing cytology with human papillomavirus screening. Lancet Oncol 2009;10:935-6.
8. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-94.
9. Arbyn M, Bunting F, Van Ranst M, Paraskevaidis E, Martin- Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93. (Pubitemid 38256273)
10. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Diller J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99:7-11.
11. Snijders PJ, Heideman DA, Meijer CJ. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 2010;118:520-8.
12. Benoy I, Vanden Broeck D, Ruymbeke MJ, Sahebali S, Arbyn M, Bogers JJ, et al. Prior knowledge of HPV status improves detection of CIN2 + by cytology screening. Am J Obstet Gynecol 2011;205:569.e1-7 .
13. Vassilakos P, Saurel J, Rondez R. Direct-to-vial use of the Auto- Cyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. Acta Cytol 1999;43:65-8. (Pubitemid 29071878)
14. Boulet GA, Benoy IH, Depuydt CE, Horvath CA, Aerts M, Hens N, et al. Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia ≤ 2 in a liquid-based cytology setting ? Cancer Epidemiol Biomarkers Prev 2009;18:2992 - 9
15. Boulet GA, Horvath CA, Depuydt CE, Bogers JJ. Biomarkers in cervical screening: quantitative reverse transcriptase PCR analysis of P16INK4a expression. Eur J Cancer Prev 2010;19:35-41.
16. Micalessi IM, Horvath CA, Benoy IH, Depuydt CE, Bogers JJ. Nucleic acid sequence-based amplifi cation assay for human papillomavirus mRNA detection and typing: evidence for DNA amplifi cation. J Clin Microbiol 2010;48:2524-9.
17. Depuydt CE, Boulet GA, Horvath CA, Benoy IH, Vereecken AJ, Bogers JJ. Comparison of MY09/11 consensus PCR and typespecifi c PCRs in the detection of oncogenic HPV types. J Cell Mol Med 2007;11:881-91. (Pubitemid 47313308)
18. Depuydt CE, Leuridan E, Van Damme P, Bogers J, Vereecken AJ, Donders GG. Epidemiology of Trichomonas vaginalis and human papillomavirus infection detected by real-time PCR in fl anders. Gynecol Obstet Invest 2010;70:273-80.
19. Depuydt CE, Makar AP, Ruymbeke MJ, Benoy IH, Vereecken AJ, Bogers JJ. BD-ProExC as Adjunct molecular marker for improved detection of CIN2 + after HPV primary screening. Cancer Epidemiol Biomarkers Prev 2011;20:628-37.
20. Ernoux-Neufcoeur P, Arafa M, Decaestecker C, Duray A, Remmelink M, Leroy X, et al. Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma. J Cancer Res Clin Oncol 2011;137:173-81.
21. Heymans J, Benoy IH, Poppe W, Depuydt CE. Type-specifi c HPV genotyping improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer 2010 doi:10.1002/ ijc.25745.
22. Luchters SM, Vanden Broeck D, Chersich MF, Nel A, Delva W, Mandaliya K, et al. Association of HIV infection with distribution and viral load of HPV types in Kenya: a survey with 820 female sex workers. BMC Infect Dis 2010;10:18.
23. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24:S3/1-10.
24. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kumar JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. (Pubitemid 29406813)
25. Morris BJ. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med 2005;43:1171-7. (Pubitemid 41600666)
26. Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005;32:43-51.
27. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specifi c DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004;73:65-70. (Pubitemid 38429149)
28. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 2007;121:2787-93. (Pubitemid 350136428)
29. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24:S3/26-34.
30. Castle PE, Rodr í guez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. Br Med J 2009;339:2569.
31. Nazarenko I, Kobayashi L, Giles J, Fishman C, Chen G, Lorincz A. A novel method of HPV genotyping using Hybrid Capture sample preparation method combined with GP5 + /6 + PCR and multiplex detection on Luminex XMAP. J Virol Methods 2008;54:76-81.
32. Dalstein V, Riethmuller D, Pretet JL, Le Bail CK, Sautiere JL, Carbillet JP, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396-403. (Pubitemid 36870403)
33. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-6. (Pubitemid 38116628)
34. Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, et al. Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2189-93. (Pubitemid 30394325)
35. Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005;92:891-4. (Pubitemid 40462636)
36. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22. (Pubitemid 46020844)
37. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.